Physicians disagree with acetaminophen restrictions
This article was originally published in The Tan Sheet
Executive SummaryA large majority -- 82 percent -- of recently surveyed physicians does not agree that FDA should pull acetaminophen products off the market. HCD Research surveyed 589 physicians July 17-19 after a joint advisory panel recommended FDA remove prescription acetaminophen products from the market, but said OTC combo products could stay. It also advised the agency restrict the amount of acetaminophen in OTC tablets and lower the dose (1"Health News Daily" July 1, 2009). While 86 percent of the physicians said the panel's recommendation will not change whether they will continue prescribing acetaminophen Rx drugs or recommending OTC drugs for their patients, nearly a third -- 29 percent -- said they are more likely to discuss warnings and dosage instructions with patients who use acetaminophen products, Flemington, N.J.-based HCD said July 20
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.